INTAGESIC-MR TABLET
Out of Stock
Intagesic MR Tablet by Intas Pharmaceuticals Ltd. is a clinically formulated fixed-dose combination oral analgesic and muscle relaxant designed to address one of the most commonly encountered yet debilitating clinical presentations: acute musculoskeletal pain compounded by involuntary muscle spasm and localised inflammation. Musculoskeletal pain arising from sprains, strains, soft tissue trauma, back injuries, post-surgical oedema, and conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis involves a complex, overlapping cascade of peripheral prostaglandin-mediated inflammation, central pain sensitisation, and reflexive muscle guarding that no single drug class can fully resolve. Intagesic MR Tablet targets all three components of this triad simultaneously through its triple-action formulation: Diclofenac Sodium (50 mg) as a potent NSAID targeting peripheral and central COX-mediated inflammation, Paracetamol (325 mg) as a synergistic central analgesic and antipyretic, and Chlorzoxazone (250 mg) as a centrally acting skeletal muscle relaxant, together delivering faster, broader, and more clinically meaningful pain relief than any single agent alone. This is a Schedule H prescription medicine and must only be used under the supervision of a qualified medical professional. Animeal is proud to offer Intagesic MR Tablet as part of our curated range of trusted prescription pain management solutions.
Ingredients:
Diclofenac Sodium (50 mg): Diclofenac sodium is a potent non-selective non-steroidal anti-inflammatory drug (NSAID) that exerts its analgesic, anti-inflammatory, and mild antipyretic effects through the inhibition of both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) isoenzymes. These enzymes catalyse the conversion of arachidonic acid to prostaglandin H2, the precursor to inflammatory prostaglandins (PGE2, PGI2) and thromboxane A2. By blocking this enzymatic step, Diclofenac reduces prostaglandin synthesis at the site of tissue injury, thereby diminishing vascular permeability, peripheral sensitisation of nociceptors, and localised oedema. At the spinal level, reduced prostaglandin availability attenuates central sensitisation, lowering the amplification of pain signals ascending to the cortex. Diclofenac has a rapid oral absorption profile with peak plasma concentrations achieved within one to two hours, making it effective for both acute and subacute pain states.
Paracetamol / Acetaminophen (325 mg): Paracetamol functions as a centrally acting analgesic and antipyretic through a mechanism distinct from classical NSAIDs. It is understood to inhibit a COX-3 variant expressed in central nervous system tissue, reducing prostaglandin-mediated pain signal amplification in the brain and spinal cord without significant peripheral anti-inflammatory activity. Additionally, paracetamol activates the descending serotonergic pain inhibitory pathways and is thought to modulate the endocannabinoid system through its active metabolite AM404. At 325 mg in this fixed-dose combination, paracetamol serves a synergistic role: it potentiates and extends Diclofenac's analgesic efficacy by addressing central pain processing, thereby reducing the effective NSAID dose required for adequate pain control and improving the overall tolerability profile of the combination. It also contributes antipyretic activity by resetting the hypothalamic thermoregulatory set-point when fever is present.
Chlorzoxazone (250 mg): Chlorzoxazone is a centrally acting benzoxazole skeletal muscle relaxant whose primary site of action is the spinal cord and supraspinal areas of the brain. It inhibits multisynaptic reflex arcs that sustain painful muscle spasm by depressing nerve impulse transmission at the polysynaptic interneurones within the spinal cord, reducing the tonic excitatory drive that maintains reflex muscle contraction. By disrupting this spinal reflex pathway, Chlorzoxazone alleviates the involuntary muscle guarding and splinting that commonly accompanies musculoskeletal injury and inflammation, restoring voluntary range of motion, reducing secondary ischaemic pain within the muscle belly, and enabling rehabilitation through physical therapy. The mild sedative effect of chlorzoxazone also contributes to patient comfort during the acute phase of injury.
